抗VEGF玻璃体腔注射（阿柏西普）
眼科项目
≈ ¥4800-6500
(≈ $670-910)
大约30-60分钟
免责声明：本站为医疗服务机构，页面信息部分由AI协助制作。健康相关信息不构成医疗建议。如有任何疑问，请咨询医疗专业人士。详情见免责声明
项目介绍
抗VEGF玻璃体腔注射（阿柏西普）在一般公立医院参考费用约¥3360-5200，三甲医院参考费用约¥4800-6500，常用于相关诊断评估与就医安排，费用随医院及地区有所差异。
主要用途
Primary clinical use is the treatment of neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). Administered via sterile intravitreal injection every 4–8 weeks initially, then extended based on disease activity assessed by optical coherence tomography (OCT), fundus examination, and best-corrected visual acuity (BCVA). It functions by binding and neutralizing VEGF-A and Placental Growth Factor (PlGF), thereby inhibiting pathological angiogenesis and vascular leakage.
正常值范围
Not applicable — anti-VEGF intravitreal injection (aflibercept) is a therapeutic procedure, not a diagnostic laboratory test with quantitative 'values' or reference ranges. There is no 'normal range' for aflibercept concentration in clinical practice; dosing is standardized (2 mg/0.05 mL per injection) and guided by anatomical/functional response (e.g., OCT-measured retinal thickness, visual acuity), not serum or intraocular drug level thresholds.
偏低可能原因
N/A — 'Low value' is not clinically meaningful for this intervention. However, suboptimal treatment response (e.g., persistent fluid on OCT or vision loss despite injection) may result from: 1) Inadequate dosing frequency or interval extension beyond evidence-based regimens; 2) Poor patient adherence to follow-up visits; 3) Development of anti-drug antibodies (rare); 4) Underlying disease severity or resistance (e.g., chronic fibrosis, RPE atrophy); 5) Concomitant uncontrolled systemic conditions (e.g., hypertension, diabetes).
偏高可能原因
N/A — 'High value' does not apply, as aflibercept is not measured quantitatively in routine care. Potential risks associated with excessive or inappropriate use include: 1) Increased intraocular pressure spikes post-injection; 2) Cumulative intraocular inflammation or sterile endophthalmitis; 3) Accelerated cataract progression; 4) Rare systemic thromboembolic events (theoretical VEGF inhibition effect); 5) Retinal pigment epithelium (RPE) tears in eyes with large pigment epithelial detachments.